Why do local academic partnerships play a key role in nuclear medicine?

Because radiopharmaceutical innovation is no longer driven solely by the idea of a new radiotracer. It also depends on the ability to characterize, control and qualify compounds under sometimes demanding conditions: limited sample volumes, highly specific analytical methods, requirements for rapid execution and radioprotection.

In this fast-evolving ecosystem, Trasis is committed to building bridges between research, where new tracers and approaches emerge, production, where reproducibility and compliance are critical, and innovation, which requires agility and responsiveness.

By connecting these dimensions, we contribute every day to structuring and advancing MedTech & Life Sciences applied to nuclear medicine, in collaboration with the stakeholders shaping its future.

Unlocking analyses that are not feasible “in-house”

Some analytical challenges require state-of-the-art equipment, specialized methods and dedicated expertise that are difficult to fully internalize within an industrial organization, especially when needs are highly specific or occasional.

This is precisely where local academic partners bring decisive value: rapid access to advanced analytical capabilities, direct scientific exchange, and the ability to tailor approaches to the realities of R&D and industrialization.

A concrete example: collaboration with UCLouvain via the MOCA platform

In this context, Trasis collaborates with UCLouvain through the MOCA platform (Mineral & Organic Chemical Analysis).MOCA provides access to advanced analytical instruments and scientific expertise capable of addressing targeted questions – particularly when development constraints require non-standard methodological choices.

Accelerating innovation without compromising on quality

This type of collaboration enables Trasis to:

access specific analytical capabilities adapted to industrial constraints,
maintain the agility required during development phases,
contribute to solutions that meet quality control and robustness requirements, essential for moving from proof of concept to production.

Innovation in nuclear medicine is collective

We firmly believe that by bringing together infrastructures, expertise and skills – from industry and academia – we help push the boundaries of what is possible, for the benefit of the ecosystem and, ultimately, patients.

When academic expertise unlocks innovation in radiopharmacy